Osteoprotegerin and its ligands for regulating the osteal resorption: experimental and clinical application aspects under estrogen deficiency conditions

Abstract

Modem conceptions concerning the role of OPG-RANK-RANKL system in a local paracrinic mechanism of the regulation of osteoclastogenesis and osteal resorption processes are presented in this article. Here, results of the first clinical researches of prognostic signification of ORG determinations for estimating disruption manifestations in osteal metabolism under estrogen deficiency conditions as well as data on the OPG use as an anti-resorbable agent at the treatment of post-menopausal osteoporosis.

Keywords

severe deficiency states / osteoprotegerin / disorders in bone metabolism / postmenopausal osteoporosis

References

[1] Шварц Г.Я. Фармакотерапия остеопороза (лекарственные средства для лечения и профилактики)//М.: Медицинское формационное агенство, 2002.— 368 с.

[2] Barengolts E.I., Berman М., Kukreja S.C. et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women//Calcif Tissue Int, 1998.— P. 62, 209-213.

[3] Bekker P.J., Holloway D., Nalanishi A. et al. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women//J. Bone Miner Res, 1999; 14(Suppl 1): S.180.

[4] Bomefalk E., Dahlen I., Johannsson G. et al. Serum levels of osteoprotegerin: effect of glucocorticoids and growth hormone //Bone, 1998; 23(Suppl 1): S.486.

[5] Burgess T.L., Qian Y., Kaufman S. et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts//J Cell Biol, 1999; 145:527-538.

[6] Fahrleitner A., Dobning H., Leb G. et al. Osteoprotegerin serum levels in women: influence of age, bone mass, bone turnover and fracture status//Osteoporosis Int, 2002; 13 (Suppl.1): P. 161MO.

[7] Fuller К., Wong В., Fox S. et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts//J. Exp. Med.— 1998; 188: 997-1001.

[8] Hofbauer L.C. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism//Eur. J. Endocrinol, 1999; 141:195-210.

[9] Hofbauer L.C., Khosla S., Dunstan C.R. et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteobastic cells//Endocrinology, 1999; 140: 4367-4370.

[10] Hofbauer L.C., Khosla S., Dunstan C.R. et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption//J. Bone Miner Res, 2000; 15: 2-12.

[11] Hsu H., Lacey D.L., Dunstan C.R. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand//Proc Natl Acad Sci USA, 1999; 96: 3540-3545.

[12] Kong Y.Y. , Yoshida H, Sarosi I. Et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis//Nature, 1999; 397:315—323.

[13] Kostenuik P.J., Shalbhoub V. Osteoproregerin: a physiological and pharmacological inhibitor of bone resorption//Curr Pharm Design.— 2001.- Vol. 7.— P. 613-635.

[14] Kwon B.S., Wang S., Udagawa N. et al. TR-1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption//FASEB J.— 1998; 12: 845-854.

[15] Lacey D.L., Timms E., Tan H.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation//Cell.— 1998; 93: 165-176.

[16] Mizuno A., Amizuka N., Irie K. et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteo- protegerin//Biochem Biophys Res Commun.— 1998; 247: 610-615.

[17] Riggs B.L., Melton, III L.J., Atkinson E.J. et al. Evidence the postmenopausal women with vertebral fractures due to type I osteoporosis have enhanced responsiveness of bone to estrogen deficiency//Osteoporosis Int.— 2002; 13 (Suppl 1): P-33MO.

[18] Rogers A., Pereda C.A., Naylor K.E. et al. Absence of a change in circulating levels of osteoprotegerin in response to subcutaneous estradiol implant in postmenopausal women//Osteoporosis Int.— 2002; 13(Suppl 1): P-328MO

[19] Schevde N.K, Bendixen A.C., Maruyama M. et al. Estrogen inhibits RANKL stimulated osteoclastogenesis in isolated murine myeloid progenitors and the monocytemacrophage cell line RAW 264—7//J. Bone Miner Res, 1999; 14 (Suppl 1): S.150.

[20] Simonet W.S., Lacey D.L., Dunstan C.R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments]//Cell.— 1997; 89: 309-319.

[21] Solari F., Jurdic P. Nouveaux concepts sur I'origine des osteoclastes: relation avec les macrophages normaux et inflammatories//Medicine/Sciences.— 1997; 13: 1285-1293.

[22] Srivastava S.K., Weitzmann M.N., Chaudhari L.R. et al. Estrogen decreases the responsiveness osteoclast precursors to OPGL by down regulating OPGL induced JNK activity//J. Bone Miner Res.— 1999; 14 (Suppl 1): S.177.

[23] Suda T., Takahashi N., Udagawa N. et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families//Endocr Rev.— 1999; 20: 345-357.

[24] Tan K.B., Harrop J., Reddy M. et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non- hematopoietic cells //Gene.— 1997; 204:35-46.

[25] Tsuda E., Goto M., Mochizuki S. et al. Isolation of a novel cytokine from human fibroblast that specifically inhibits osteoclastogenesis//Biochem Biophys Res Commun.— 1997; 234:137-142.

[26] Vidal NO., Brandstrom H, Jonsson K.B. et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down regulation by glucocorticoids//J. Endocrinol.— 1998; 159:191—195.

[27] Wong B.R., Josier R., Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function//J. Leukoc Biol.— 1999; 65: 715-724.

[28] Yasuda H, Shima N., Nakagawa N. et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by witch OPG/OCIF inhibits osteoclastogenesis in vitro//Endocrinology.— 1998; 139: 1329-1337.

[29] Yasuda H, Shima N., Nakagawa N. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteo- clastogenesis-inhibitory factor and is identical to TRANCE/RANKL//Proc Natl Acad Sci USA.- 1998; 95: 3597-3602.

[30] Yun T.J. , Chaudhary P.M., Shu G.L. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40//J. Immunol.— 1998; 161: 6113-6121.

RIGHTS & PERMISSIONS

Eсо-Vector